Jumpstart

Jumpstart Ventures is a Cleveland-based venture capital firm established in 2011. The firm focuses on investing in startups that are innovating within sectors such as software, healthcare information technology, biotechnology, and business-to-business solutions. Jumpstart Ventures aims to partner with entrepreneurs who possess a blend of humility and ambition, supporting those who are dedicated to creating meaningful and positive changes in their communities through intelligent innovation. The firm seeks to back founders who are launching companies with a strong purpose and a commitment to impactful solutions.

Joshua Borstein Ph.D

Investment Principal

Hardik Desai

Managing Partner & NEXT Fund Manager

Bethany George

Partner, Investments

Anne Richie

Venture Partner

Past deals in Ohio

Centerline Biomedical

Series B in 2022
Centerline Biomedical, Inc. is a Cleveland-based company founded in 2014, focused on developing advanced navigation systems for interventional vascular procedures. The company specializes in a non-x-ray based, three-dimensional GPS surgical navigation technology that enhances the precision and outcomes of endovascular procedures while significantly reducing radiation exposure for both patients and healthcare providers. This innovative system assists surgeons in accurately navigating catheters and guide wires through the complex three-dimensional anatomy of patients with vascular diseases, ultimately enabling safer and more effective image-guided surgeries. The technology is rooted in research and development from the Cleveland Clinic, highlighting its commitment to improving surgical practices in the medical field.

Felux

Series A in 2022
B2B Marketplace for Steel & Aluminum

My One Medical Source

Seed Round in 2022
My One Medical SourceĀ® (MOMS), a health-tech company connecting diagnostic clinical labs with medically-trained personnel to prepare and ship specimen to designated labs.

Thrivable

Seed Round in 2021
Thrivable is a technology platform that helps health care organizations tap into a comprehensive patient database to do market research activities. Right now the market research process is slow, expensive, and frustrating for companies. Thrivable has created a solution that reduces the time it takes to get insights from months to hours.

Thermalin

Seed Round in 2010
Thermalin hopes to disrupt the $30B insulin/insulin delivery market with a disposable, postage-stamp-sized glucose management system enabled by our first-in-class stabilized, highly concentrated, and ultra-rapid acting insulin. This same new insulin molecule in "ordinary" (U-100) concentration will enable the factory-filling of reservoirs for existing insulin pumps. In addition to this lead program, Thermalin is developing partnerships on no-cold-chain basal and mix insulins and on glucose-responsive insulins.